Quinn Emanuel Strengthens Its Pharma Patent Team

(No Ratings Yet)

Loading...

Quinn Emanuel Urquhart & Sullivan LLP announced on Tuesday that it had added three top litigators in Pharmaceutical related matters to their team. The trio of Intellectual Property lawyers from Jones Day would be joining Quinn Emanuel’s New York Office.

All three lawyers, Dominic “Nick” Cerrito, Eric Stops and Evangeline Shih have earned huge reputations in intellectual property disputes in the pharmaceutical industry.

Managing partner John Quinn of Quinn and Emmanuel said “Life Sciences is one of the fastest areas of growth at the firm.  The team will join a talented group of lawyers at our firm who excel at handling complex, high-stakes patent litigation for pharmaceutical companies.  It will greatly benefit our clients in the industry.”

  

What

Where

Search Jobs

Nick Cerrito is the former co-head of the pharmaceutical group of Jones Day and he focuses on Hatch-Waxman litigation and the cross-border areas of patent and FDA laws. Besides representing giant pharmaceutical companies and litigating over a wide variety of products belonging to different therapeutic classes, Cerrito’s practice also includes due diligence in pharma product acquisition, strategic planning and formulation of patent prosecution strategies. Cerrito has been listed in The Best Lawyers in America and as a BTI Client Service All-Star.

Eric Stops specializes in almost similar areas including Hatch-Waxman patent litigation for innovator pharmaceutical companies. He is an expert on FDA issues, patent portfolio evaluation, and expert counsel on the patentability of inventions.

Evangeline Shih is listed as a “Rising Star” Super Lawyer in 2011 and also focuses on Hatch-Waxman litigation and client counseling. She is a subject expert in patent protection, formulating opinions, and counseling with regard to freedom to operate, infringement, patentability of innovations, and validity of patents. She has experience in working with the law of a wide range of biological and medical device products, besides pharmaceutical products.

With the acquisition of the ‘pharma trio’ Quinn Emanuel underlined its future strategy of continuing to lead in IP law and pharma litigation.